Scarica l'app Stockscreener
0.70
1.41%
-0.01
Dopo l'orario di chiusura:
.70
Precedente Chiudi:
$0.71
Aprire:
$0.75
Volume 24 ore:
49,930
Relative Volume:
0.84
Capitalizzazione di mercato:
$24.19M
Reddito:
-
Utile/perdita netta:
$-563.30K
Rapporto P/E:
-3.507
EPS:
-0.1996
Flusso di cassa netto:
$-22.23M
1 W Prestazione:
-12.52%
1M Prestazione:
-23.87%
6M Prestazione:
-46.56%
1 anno Prestazione:
-66.51%
Intervallo 1D:
$0.6208
$0.76
Intervallo di 1 settimana:
$0.6208
$0.8446
Portata 52W:
$0.6208
$2.61
Promis Neurosciences Inc Stock (PMN) Company Profile
Nome
Promis Neurosciences Inc
Settore
Industria
Telefono
416-847-6898
Indirizzo
SUITE 200, 1920 YONGE STREET, TORONTO
Confronta PMN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.70 | 24.19M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Promis Neurosciences Inc Borsa (PMN) Ultime notizie
ProMIS Neurosciences stock hits 52-week low at $0.62 - Investing.com India
ProMIS Neurosciences stock hits 52-week low at $0.62 By Investing.com - Investing.com South Africa
ProMIS Neurosciences’ (PMN) “Buy” Rating Reiterated at Guggenheim - Defense World
ProMIS Neurosciences begins Alzheimer's trial dosing - Investing.com India
ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial - TipRanks
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement - The Manila Times
ProMIS Neurosciences begins Alzheimer’s trial dosing - Investing.com
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease - GlobeNewswire
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for ... - The Bakersfield Californian
Multiple System Atrophy Clinical Trials and Pipeline 2025: EMA, - openPR
ProMIS Neurosciences Announces COO Position Termination - TipRanks
ProMIS Neurosciences stock hits 52-week low at $0.85 By Investing.com - Investing.com Nigeria
ProMIS Neurosciences dismisses COO position - MSN
ProMIS Neurosciences announces COO departure - Investing.com
ProMIS Neurosciences stock hits 52-week low at $0.85 - Investing.com
Promis Neurosciences chief scientific officer buys $14,595 in shares - MSN
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel - GlobeNewswire
StockNews.com Initiates Coverage on Beasley Broadcast Group (NASDAQ:BBGI) - Defense World
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference - The Manila Times
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Inside ProMIS's Game-Changing Approach to Neurodegenerative Diseases: CEO Reveals Latest Developments - StockTitan
ProMIS Neurosciences Updates Corporate Presentation in Recent 8-K Filing - Defense World
Vanda Pharmaceuticals Files for New Drug Application for Tradipitant for Motion Sickness Treatment - Defense World
ProMIS Neurosciences Highlights Neurodegenerative Disease Focus - TipRanks
ProMIS Neurosciences launch Phase Ia AβO Alzheimer’s trial - MSN
LANTRONIX Appoints Brent Stringham as Chief Financial OfficerIRVINE, Calif. – Lantronix, Inc. (NASDAQ: LTRX), a prominent provider of IoT compute and connectivity solutions, has announced the appointment of Brent Stringham as its new Chief Financial - ETF Daily News
ProMIS Neurosciences Issues Letter to Shareholders - Markets Insider
Crude Oil WTI (CLN25) Quote - The Globe and Mail
Crude Oil Brent (F) (QAJ23) Quote - The Globe and Mail
ProMIS Neurosciences Launches Phase 1b Trial for Alzheimer’s - TipRanks
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease - The Manila Times
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones - The Manila Times
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease - GlobeNewswire
ProMIS Neurosciences faces Nasdaq delisting over share price - Investing.com
Nonfat Dry Milk (DFZ25) Quote - The Globe and Mail
Berkshire Hathaway Cl B (BRK-B-N) QuotePress Release - The Globe and Mail
ProMIS Neurosciences (NASDAQ:PMN) Shares Up 2.8% – Should You Buy? - Defense World
ProMIS Neurosciences stock hits 52-week low at $0.88 By Investing.com - Investing.com Nigeria
ProMIS Neurosciences stock hits 52-week low at $0.88 - Investing.com
Vertiv Holdings Llc. (VRT-N) QuotePress Release - The Globe and Mail
ProMIS Neurosciences, Inc. (NASDAQ:PMN) Short Interest Down 16.6% in November - Defense World
ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference - GlobeNewswire
ProMIS Neurosciences stock hits 52-week low at $0.91 - Investing.com
ProMIS Neurosciences stock hits 52-week low at $0.91 By Investing.com - Investing.com Australia
13th Alzheimers and Parkinsons Drug Development Summit - PharmiWeb.com
ProMIS Neurosciences Announces Third Quarter Financial Results and Recent HighlightsOn November 14, 2024, ProMIS Neurosciences Inc. (Nasdaq: PMN) shared its financial outcomes for the third quarter ended September 30, 2024. The company provide - Defense World
ProMIS Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
GREAT POINT PARTNERS LLC Acquires Shares in ProMIS Neurosciences Inc - GuruFocus.com
Promis Neurosciences Inc Azioni (PMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Promis Neurosciences Inc Azioni (PMN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shafmaster Madge K. | Director |
Sep 24 '24 |
Buy |
1.30 |
70,000 |
91,028 |
208,333 |
| Shafmaster Madge K. | Director |
Sep 23 '24 |
Buy |
1.28 |
70,000 |
89,656 |
138,333 |
| Shafmaster Madge K. | Director |
Sep 20 '24 |
Buy |
1.25 |
60,000 |
75,066 |
68,333 |
| GORDON MICHAEL S | 10% Owner |
Sep 16 '24 |
Buy |
1.22 |
76,931 |
94,071 |
76,931 |
| GORDON MICHAEL S | 10% Owner |
Sep 17 '24 |
Buy |
1.40 |
16,292 |
22,809 |
93,223 |
| Kirwin Patrick D. | Director |
Aug 14 '24 |
Buy |
1.25 |
10,000 |
12,492 |
62,983 |
6.45%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):